NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 97-106

  Zha, Xiaojun ^a   Hu, Zhongdong ^b,c   Ji, Shuang ^a   Jin, Fuquan ^a   Jiang, Keguo ^a   Li, Chunjia ^b   Zhao, Pan ^a   Tu, Zhenzhen ^a   Chen, Xianguo ^a   Di, Lijun ^a,d   Zhou, Haisheng ^a   Zhang, Hongbing ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d University of Macau   (Macao)

Author keywords

Aerobic glycolysis; Glut3; MTOR; NF B; Tumorigenesis

Indexed keywords

GLUCOSE TRANSPORTER 3; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; MULTIPROTEIN COMPLEX; RAPAMYCIN; SLC2A3 PROTEIN, HUMAN; SLC2A3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN;

AEROBIC GLYCOLYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; EMBRYO; GLYCOLYSIS; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME;

MAMMALIA; MUS MUSCULUS;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASMS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RATS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84922260439     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.001     Document Type: Article

References (40)

1. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Elf S.E., Chen J. Targeting glucose metabolism in patients with cancer. Cancer 2014, 120:774-780.
4. Adekola K., Rosen S.T., Shanmugam M. Glucose transporters in cancer metabolism. Curr. Opin. Oncol 2012, 24:650-654.
5. El Mjiyad N., Caro-Maldonado A., Ramirez-Peinado S., Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30:253-264.
6. Simpson I.A., Dwyer D., Malide D., Moley K.H., Travis A., Vannucci S.J. The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol. Endocrinol. Metab 2008, 295:E242-E253.
7. Szablewski L. Expression of glucose transporters in cancers. Biochim. Biophys. Acta 2013, 1835:164-169.
8. Calvo M.B., Figueroa A., Pulido E.G., Campelo R.G., Aparicio L.A. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol 2010, 2010. 10.1155/2010/205357.
9. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci 2013, 16:1373-1382.
10. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
11. Zha X., Wang F., Wang Y., He S., Jing Y., Wu X., et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 2011, 71:13-18.
12. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
13. Zaytseva Y.Y., Valentino J.D., Gulhati P., Evers B.M. mTOR inhibitors in cancer therapy. Cancer Lett 2012, 319:1-7.
14. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest 2007, 117:730-738.
15. Zha X., Hu Z., He S., Wang F., Shen H., Zhang H. TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade. Cancer Lett 2011, 313:211-217.
16. Franz D.N. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics Targ. Ther 2013, 7:211-221.
17. Ma J., Meng Y., Kwiatkowski D.J., Chen X., Peng H., Sun Q., et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest 2010, 120:103-114.
18. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el Hashemite N., et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet 2002, 11:525-534.
19. Howe S.R., Gottardis M.M., Everitt J.I., Goldsworthy T.L., Wolf D.C., Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol 1995, 146:1568-1579.
20. Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4129-4134.
21. Chong-Kopera H., Inoki K., Li Y., Zhu T., Garcia-Gonzalo F.R., Rosa J.L., et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem 2006, 281:8313-8316.
22. Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26:203-234.
23. Ling J., Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett 2012, 322:119-126.
24. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
25. Ayala F.R., Rocha R.M., Carvalho K.C., Carvalho A.L., da Cunha I.W., Lourenco S.V., et al. GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules 2010, 15:2374-2387.
26. Krzeslak A., Wojcik-Krowiranda K., Forma E., Jozwiak P., Romanowicz H., Bienkiewicz A., et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol. Oncol. Res 2012, 18:721-728.
27. Choo A.Y., Kim S.G., Vander Heiden M.G., Mahoney S.J., Vu H., Yoon S.O., et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol. Cell 2010, 38:487-499.
28. Lee C.H., Inoki K., Karbowniczek M., Petroulakis E., Sonenberg N., Henske E.P., et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J. 2007, 26:4812-4823.
29. Fei X., Qi M., Wu B., Song Y., Wang Y., Li T. MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett 2012, 586:392-397.
30. Ha T.K., Her N.G., Lee M.G., Ryu B.K., Lee J.H., Han J., et al. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res 2012, 72:4097-4109.
31. Copland J.A., Pardini A.W., Wood T.G., Yin D., Green A., Bodenburg Y.H., et al. IGF-1 controls GLUT3 expression in muscle via the transcriptional factor Sp1. Biochim. Biophys. Acta 2007, 1769:631-640.
32. Kawauchi K., Araki K., Tobiume K., Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol 2008, 10:611-618.
33. Mimura I., Nangaku M., Kanki Y., Tsutsumi S., Inoue T., Kohro T., et al. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol. Cell. Biol 2012, 32:3018-3032.
34. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
35. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008, 22:1490-1500.
36. Parra V., Verdejo H.E., Iglewski M., Del Campo A., Troncoso R., Jones D., et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt-mTOR-NFkappaB-Opa-1 signaling pathway. Diabetes 2014, 63:75-88.
37. Tanaka K., Babic I., Nathanson D., Akhavan D., Guo D., Gini B., et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011, 1:524-538.
38. Wang F., Chen X., Li C., Sun Q., Chen Y., Wang Y., et al. Pivotal role of augmented alphaB-crystallin in tumor development induced by deficient TSC1/2 complex. Oncogene 2013, 33:4352-4358.
39. Watanabe M., Abe N., Oshikiri Y., Stanbridge E.J., Kitagawa T. Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-kappaB-dependent GLUT3 expression. Oncogenesis 2012, 1. e21.
40. Hagiwara A., Cornu M., Cybulski N., Polak P., Betz C., Trapani F., et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012, 15:725-738.